Ionis Pharmaceuticals Inc
IONS
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.15B
Close$
$-57.64
199.2% downside
Current Fair Value
199.2% downsideOvervalued by 199.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.15 Billion |
|---|---|
| Enterprise Value | $10.51 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.38 |
| Beta | 0.4 |
| Outstanding Shares | 165,419,000 |
Return
| Return on Equity | -48.16% |
|---|---|
| Return on Assets | -7.07% |
| Return on Invested Capital | -7.85% |
Valuation & Multiples
| P/E Ratio | -17.64 |
|---|---|
| PEG | 9.17 |
| Price to Sales | 9.69 |
| Price to Book Ratio | 29.07 |
| Enterprise Value to Revenue | 9.36 |
| Enterprise Value to EBIT | -49.97 |
| Enterprise Value to Net Income | -50 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | 5.51 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.91
Average shareholder expectationRevenue Estimate
$187.17 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.22
Average shareholder expectationRevenue Estimate
$181.78 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6087▼ 41.41% |
|---|---|
| Total Calls | 4,546,554▲ 180.52% |
| Total Puts | 2,767,500▲ 66.95% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 118.60%▲ 10.73% |
|---|---|
| Total Invested | $14.56B▲ 12.33% |
| Investors Holding | 554▲ 30.00% |
ESG Score
No data
About Ionis Pharmaceuticals Inc
817 employees
CEO: Brett Monia Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...